VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) — Clearmind Drugs Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech firm centered on discovery and improvement of novel psychedelic-derived therapeutics to unravel main undertreated well being issues, introduced that it has determined to problem 122,160 frequent shares within the capital of the Firm (“Shares”) in lieu of cost of $10,000, month-to-month, beginning Could 1st 2022, to consultants of the Firm.
All Shares will solely be subjected to these restrictions designated in relevant securities legal guidelines.
About Clearmind Drugs Inc.
Clearmind is a psychedelic pharmaceutical biotech firm centered on the invention and improvement of novel psychedelic-derived therapeutics to unravel widespread and underserved well being issues, together with alcohol use dysfunction. Its main goal is to analysis and develop psychedelic-based compounds and try to commercialize them as regulated medicines, meals or dietary supplements.
The Firm’s mental portfolio at present consists of 4 patent households. The Firm intends to hunt further patents for its compounds every time warranted and can stay opportunistic relating to the acquisition of further mental property to construct its portfolio.
Shares of Clearmind are listed for buying and selling on the Canadian Securities Alternate below the image “CMND“, the Frankfurt Inventory Alternate below the image “CWYO” and on the OTC Markets below the image “CMNDF“.
This information launch might include forward-looking statements and knowledge based mostly on present expectations. These statements shouldn’t be learn as ensures of future efficiency or outcomes. Such statements contain recognized and unknown dangers, uncertainties and different components that will trigger precise outcomes, efficiency or achievements to be materially totally different from these implied by such statements. Such statements embrace submission of the related documentation inside the required timeframe to the satisfaction of the related regulators and elevating ample financing to finish the Firm’s enterprise technique. There is no such thing as a certainty that any of those occasions will happen. Though such statements are based mostly on administration’s affordable assumptions, there might be no assurance that such assumptions will show to be right. We assume no duty to replace or revise them to mirror new occasions or circumstances.
Investing into early-stage corporations inherently carries a excessive diploma of threat, and funding into securities of the Firm shall be thought-about extremely speculative.
This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase, nor shall there be any sale of the securities in any province by which such provide, solicitation or sale could be illegal. The securities issued, or to be issued, below the Non-public Placement haven’t been, and won’t be, registered below the USA Securities Act of 1933, as amended, and is probably not provided or offered in the USA absent registration or an relevant exemption from registration necessities.
Neither the Canadian Securities Alternate (the “CSE”) nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the CSE) accepts duty for the adequacy or accuracy of this launch.